Status:
UNKNOWN
Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone
Lead Sponsor:
Medical University of Vienna
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Hepatocellular carcinoma (HCC) is a consequence of liver cirrhosis. In early tumour stages, tumour resection or liver transplantation are therapeutic options; later tumour stages may be treated with l...
Detailed Description
This is a randomized two-arm parallel group study. * Study group: PEI + long-acting somatostatin * Control group: long-acting somatostatin alone Aims of the study: * Does treatment with PEI+ long-a...
Eligibility Criteria
Inclusion
- Histologically-proven hepatocellular carcinoma
- Treatable with percutaneous ethanol instillation
- Inoperable tumour
- Age 18-85 years
Exclusion
- Liver cirrhosis Child C
- Tumour diameter \> 8 cm
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00121914
Start Date
October 1 2000
End Date
July 1 2005
Last Update
October 18 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaetsklinik fuer Innere Medizin IV / Gastroenterologie und Hepatologie
Vienna, Vienna, Austria, 1090